Syndax Pharmaceuticals (SNDX) Receivables - Net (2024 - 2026)

Syndax Pharmaceuticals' Receivables - Net history runs 3 years deep, the most recent figure standing at $38.1 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 142.44% year-over-year to $38.1 million; the TTM figure through Mar 2026 stood at $38.1 million (up 142.44% YoY), while the FY2025 annual figure was $38.0 million, up 399.82% from the prior year.
• Receivables - Net for Q1 2026 stood at $38.1 million, roughly flat from $38.0 million in the prior quarter.
• The five-year high for Receivables - Net was $38.1 million in Q1 2026, with the low at $7.6 million in Q4 2024.
• The 3-year median for Receivables - Net is $22.4 million (2025), against an average of $24.0 million.
• The sharpest annual moves came in 2025 and 2026: Receivables - Net surged 399.82% in 2025, then surged 142.44% in 2026.
• Syndax Pharmaceuticals' Receivables - Net stood at $7.6 million in 2024, then soared by 399.82% to $38.0 million in 2025, then increased by 0.32% to $38.1 million in 2026.
• Business Quant data shows SNDX's Receivables - Net at $38.1 million in Q1 2026, $38.0 million in Q4 2025, and $25.4 million in Q3 2025.